Novian Health

  • About Us
    • Overview
    • Management
    • Board Of Directors
    • Investors
  • Research & Products
    • Novilase® Breast Therapy
    • Clinical Trials & Registries
    • Publications
    • Intellectual Property
  • News
    • News & Press Releases
    • Media Coverage
    • Upcoming Events
  • Contact
    • Careers

Qualifying Therapeutic Discovery Project Grant

November 4, 2010 by Novian Health

November 4, 2010
Contact: Liz Dowling, (800) 386-0157
Dowling & Dennis Public Relations
E-mail:Liz@DowlingDennis.net

Novian Health Awarded a $244,479 Qualifying Therapeutic Discovery Project Grant

CHICAGO – Novian Health, developer of Novilase® Breast Therapy, announced that it was awarded a grant of $244,479 under the U.S. Government’s Qualifying Therapeutic Discovery Project (QTDP) program.

QTDP is specifically designed to promote medical research that could improve health and save lives. The program targeted projects in new innovative therapies to prevent, diagnose, and treat acute and chronic diseases. A focus of the program is support of companies that could significantly advance the goal of curing cancer within the next 30 years and have the potential to reduce long-term health care costs in the United States.

“I am pleased that Novilase has been recognized by this program for having the potential to significantly improve breast conservation therapy for women. I am also proud of our team of professionals whose work is at the heart of this recognition and the continuing support of our investor group,” said Chip Appelbaum, Chief Executive Officer of Novian Health.

Companies that received QTDP grants were selected jointly by the Treasury Department and the Department of Health and Human Services. The grants are limited to companies with 250 or fewer employees. The Department of Treasury further allocated the available funds among the most qualified applicants, because the program was substantially oversubscribed.

About Novilase

Novilase is a laser-based device for destroying tumors. This minimally invasive alternative to conventional surgery provides a patient with a safe tumor treatment option while preserving the patient’s options for additional procedures or adjunctive therapies. The procedure is office-based and does not require general anesthetic or a hospital stay. Multiple tumors can be treated during a single procedure. Therapy outcomes can be confirmed using a variety of currently available imaging technologies and other methods. Therapy consists of physician placement of two small gauge needles into the tumor site after local anesthetic followed by initiation of the computer controlled Novilase system. Treatment times vary from 15 to 30 minutes. Additionally, Novian is now engaged in the process of seeking FDA approval that would validate the company’s treatment paradigm of malignant breast tumors. Successful completion of an FDA trial could lead to approval for treating malignant breast tumors.

About Novian Health

Novian Health Inc., located in Chicago, is a privately held company with proprietary technology for the treatment of tumors using Interstitial Laser Therapy (ILT). The company’s minimally invasive Novilase procedure uses parametrically controlled heating for the ablation of breast tumors as an alternative to surgery.

Novian Health has received its first FDA 510(k) market clearance for treating fibroadenomas (benign tumors) of the breast and currently offers Novilase at breast centers around the country that are participating in its ABLATE registry. Approval for treatment of malignant tumors will also be sought. Novilase also has the potential to treat other tumors within the body.

For more information, call (312) 266-7200 or access www.novianhealth.com.

Related Posts

  • Breast Tumor Laser

Filed Under: Archives

Recent Posts

  • Novian Health Earns New Product Innovation Award for Novilase Breast Therapy (6 December 2022)
  • Novian Health Gains FDA Breakthrough Designation for Novilase Breast Therapy (28 September 2021)
  • Novian Health Inc. Announces the Second Close of Convertible Note Financing (23 August 2021)
  • Novian Health Inc. Announces the First Close of Convertible Note Financing (28 July 2021)
  • Novian Health to Present at the Cavendish Global Summit on February 25, 2021 (12 February 2021)

ARCHIVES

  • December 2022
  • September 2021
  • August 2021
  • July 2021
  • February 2021
  • September 2020
  • June 2020
  • September 2019
  • July 2019
  • June 2019
  • December 2015
  • December 2014
  • September 2014
  • May 2014
  • December 2013
  • April 2013
  • February 2013
  • April 2012
  • October 2011
  • September 2011
  • July 2011
  • November 2010
  • December 2009
  • November 2009
  • October 2009
  • May 2009
  • June 2008
  • March 2008
  • October 2007
  • June 2007

Categories

  • Archives
  • Press Release 2011
  • Press Release 2012
  • Press Release 2013
  • Press Release 2014
  • Press Release 2015
  • Press Release 2019
  • Press Release 2020
  • Press Release 2021
  • Press Release 2022

CONTACT US

Novian Health Inc.
(Headquarters)
Novian Health Inc.
(Manufacturing)
222 W Merchandise Mart Plaza
Suite 1230
Chicago, Illinois 60654
1205 E State Avenue
Tonganoxie, KS 66086
Office: 312-266-7200 Office: 312-266-7200
Fax: 312-266-7202 Fax: 312-266-7202
Email: info@novianhealth.com Email: info@novianhealth.com

    

LATEST NEWS

  • Novian Health Earns New Product Innovation Award for Novilase Breast Therapy (6 December 2022)
  • Novian Health Gains FDA Breakthrough Designation for Novilase Breast Therapy (28 September 2021)
  • Novian Health Inc. Announces the Second Close of Convertible Note Financing (23 August 2021)
  • Novian Health Inc. Announces the First Close of Convertible Note Financing (28 July 2021)
  • Novian Health to Present at the Cavendish Global Summit on February 25, 2021 (12 February 2021)

Copyright © 2023 Novian Health. All Rights Reserved. Powered by